Spexis Announces Changes to the Executive Committee - Seite 2

“After being intimately involved in the formation of Spexis and as Chief Financial Officer since, it is time for me to take on a new challenge,” remarked Hernan Levett. “I would like to thank Jeff, the board of directors, our shareholders, and the entire Spexis team for their trust, support, and commitment. It has been a pleasure to serve the company and I wish the team all the best as they move into an exciting chapter in the company’s future.”

Biographical summaries of Martin and Muriel can be found on our website www.spexisbio.com

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.

 

For further information please contact:

For Investors:    Stephen Jasper Managing Director Gilmartin Group [e-mail]   For Media:    Dr. Stephan Feldhaus Feldhaus & Partner [phone] [e-mail]

 

Disclaimer

This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.